UPDATE: Piper Jaffray Lowers PT on Supernus Pharmaceuticals on Earnings

Piper Jaffray analyst David Amsellem published a report on Supernus Pharmaceuticals

that reiterated its Overweight rating and lowered the price target from $15 to $14 per share. Piper Jaffray reported that, “Supernus reported a 4Q12 net loss per share of ($0.51) and finished 2012 with $92M in cash on hand. Management provided favorable color regarding the recent Oxtellar XR launch, noting particularly strong managed care access for the product. With one product now on the market and another launch (i.e., Trokendi XR, which should launch in 3Q13) on the horizon (each with sales potential in excess of $150M in our view), plus an advancing pipeline focused on ADHD/psychiatry, SUPN shares remain attractive in our view in the context of a market cap of near $200M.” Shares of Supernus Pharmaceuticals closed at $6.90 on Thursday.